Dewpoint congratulates our scientific founder, Tony Hyman, for his election to the German Academy of Sciences Leopoldina. This prestigious award […]

BOSTON, June 16, 2021 — Dewpoint Therapeutics, the biomolecular condensates company, today announced the appointment of Michael Wagner, Ph.D., as Senior […]

BOSTON, April 21, 2021 — Dewpoint Therapeutics, the biomolecular condensates company, today announced the appointment of Isaac Klein, M.D., Ph.D., as Chief […]

A new article focused on fluorescence methods to characterize biomolecular condensates was published in Methods in Microbiology. The article, co-authored […]

BOSTON, March 9, 2021 – Volastra Therapeutics and Dewpoint Therapeutics today announced a research and development partnership to discover novel modulators of biomolecular condensates […]

BOSTON, February 16, 2021 – Dewpoint Therapeutics, the biomolecular condensates company, today announced that it has appointed Regina Barzilay, Ph.D., to its […]

BOSTON, February 11, 2021 — Dewpoint Therapeutics, the biomolecular condensates company, today announced it has appointed Joel Sendek as Chief Financial Officer […]

A Nature review of condensate focused start-ups has described Dewpoint as the “field’s frontrunner’. The article has profiled three condensate […]

BOSTON, January 6, 2021 —  Dewpoint Therapeutics, the biomolecular condensates company, today announced a new research collaboration with Pfizer (NYSE: PFE) […]

BOSTON, December 9, 2020 — Dewpoint Therapeutics, the biomolecular condensates company, today announced it has appointed Kara Carter, Ph.D., as Senior […]